# Pizarra — PT-pseudo_34647958aba3 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_34647958aba3
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 7.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.121 ng/mL²
  - PSA velocity: 2.45 ng/mL/yr
  - Prior PSA: 4.9 ng/mL
  - Prostate volume: 63.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.0 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis
  - Problem list / PMHx: Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 7.6 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 63 mL. DRE nodus. csPCa 0.00.

Vitals: weight 67 kg, height 179 cm, BMI 20.9, BP 128/95 mmHg, HR 83 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2021).

Chief complaint: Clinical review requested due to escalating prostate-specific antigen values alongside established biopsy history.

History: This semi-retired harbour pilot, aged 65, has maintained routine monitoring since his initial biopsy uncovered low-grade disease. He shares a household with his spouse and experiences negligible lower urinary tract symptoms, scoring a mere 4 on the IPSS questionnaire. His medical routine includes periodic visits to a sleep clinic for suspected obstructive sleep apnoea, alongside a recently completed chest radiograph. Daily activities remain active, featuring regular gardening and a modest alcohol intake of approximately nine units per week. A complete cessation of tobacco occurred in 2021, marking the end of a 34 pack-year consumption. Osteoarthritic discomfort remains controlled with occasional paracetamol, while his appointment scheduling consistently favors mornings to accommodate public transit availability.

Physical examination: DRE — texture: firm; mobility: fixed; asymmetry: prominent nodule localized to the left peripheral zone. Systemic assessment reveals normal vital parameters without evidence of disseminated disease.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 9 units / week; exercise Gardening, no structured exercise; IPSS score: 4/35 (mild LUTS).

Recent other appointments: Sleep clinic — suspected obstructive sleep apnoea; Radiology — chest X-ray (routine).
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.41 +/- 0.14   (95% CI 0.14-0.69)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.14  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.98 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the initial panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the PI-RADS 5 score in conjunction with the rising PSA velocity (2.45 ng/mL/yr) and the prior positive biopsy status.
The prior did not weigh the specific PSA density (0.121 ng/mL²) or the specific prostate volume (63.0 mL) against the guideline risk matrix.
The prior did not consider the implication of the prior positive biopsy status in the context of the current high-risk imaging finding.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.41 +/- 0.14. The wide epistemic error bar (dp = 0.14) indicates the model cannot reliably distinguish between biopsy and no biopsy for this patient.
The prior might be wrong because it failed to account for the high PI-RADS 5 score, which, according to guideline search results, places the patient in a high-risk category for csPCa.
The prior might be wrong because it did not adequately weigh the combination of a high PI-RADS 5 and a rising PSA velocity, which together suggest a need for further investigation beyond the initial panel.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?

GUIDELINE ANCHOR
Guideline search indicates that PI-RADS 5 lesions are associated with an 83% detection rate of csPCa in biopsy-naïve men, constraining the decision towards further investigation.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion within the left peripheral zone, 18 mm in diameter, focal enhancement. Prostate volume 63.0 mL, PSAD 0.121 ng/mL/mL. csPCa predicted probability 0.0.
get_psa_trend
PSA trend: [{"date": "Oct 2022", "val": 1.7}, {"date": "Dec 2023", "val": 2.6}, {"date": "Feb 2025", "val": 7.6}].
get_previous_notes
Previous notes: On 05 Sep 2023, a urology referral was initiated due to a prior positive biopsy. A laboratory draw in December 2023 recorded a PSA of 4.9 ng/mL.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise a specific question requiring this document.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 5 lesion within the left peripheral zone, 18 mm in diameter, focal enhancement.
- PSA trend: Rising trend from 1.7 ng/mL (Oct 2022) to 7.6 ng/mL (Feb 2025).
- Previous notes: History of a prior positive biopsy and a follow-up referral initiated in Sep 2023.

AGAINST Sampling this patient now:
- MRI report: csPCa predicted probability 0.0.

WHERE THIS LEANS
The combination of a high-risk PI-RADS 5 finding and a significantly rising PSA trajectory strongly supports further investigation via biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence, showing a PI-RADS 5 lesion and a significant rising PSA trend following a prior positive biopsy, strongly supports proceeding with a biopsy.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the PI-RADS 5 score in conjunction with the rising PSA velocity (2.45 ng/mL/yr) and the prior positive biopsy status.
The prior did not weigh the specific PSA density (0.121 ng/mL²) or the specific prostate volume (63.0 mL) against the guideline risk matrix.
The prior did not consider the implication of the prior positive biopsy status in the context of the current high-risk imaging finding.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.41 +/- 0.14. The wide epistemic error bar (dp = 0.14) indicates the model cannot reliably distinguish between biopsy and no biopsy for this patient.
The prior might be wrong because it failed to account for the high PI-RADS 5 score, which, according to guideline search results, places the patient in a high-risk category for csPCa.
The prior might be wrong because it did not adequately weigh the combination of a high PI-RADS 5 and a rising PSA velocity, which together suggest a need for further investigation beyond the initial panel.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?

GUIDELINE ANCHOR
Guideline search indicates that PI-RADS 5 lesions are associated with an 83% detection rate of csPCa in biopsy-naïve men, constraining the decision towards further investigation.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 5 lesion within the left peripheral zone, 18 mm in diameter, focal enhancement. Prostate volume 63.0 mL, PSAD 0.121 ng/mL/mL. csPCa predicted probability 0.0.
get_psa_trend
PSA trend: [{"date": "Oct 2022", "val": 1.7}, {"date": "Dec 2023", "val": 2.6}, {"date": "Feb 2025", "val": 7.6}].
get_previous_notes
Previous notes: On 05 Sep 2023, a urology referral was initiated due to a prior positive biopsy. A laboratory draw in December 2023 recorded a PSA of 4.9 ng/mL.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents did not raise a specific question requiring this document.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 5 lesion within the left peripheral zone, 18 mm in diameter, focal enhancement.
- PSA trend: Rising trend from 1.7 ng/mL (Oct 2022) to 7.6 ng/mL (Feb 2025).
- Previous notes: History of a prior positive biopsy and a follow-up referral initiated in Sep 2023.

AGAINST Sampling this patient now:
- MRI report: csPCa predicted probability 0.0.

WHERE THIS LEANS
The combination of a high-risk PI-RADS 5 finding and a significantly rising PSA trajectory strongly supports further investigation via biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully addressed by retrieving the MRI report, PSA trend, and previous notes. The evidence strongly leans towards biopsy due to the PI-RADS 5 finding and rising PSA trend, despite the prior positive biopsy status.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The conference resolved a split between deferral and biopsy, with the evidence leaning towards biopsy due to the PI-RADS 5 finding and the rising PSA trend. The statistical prior suggested no biopsy, but the retrieved evidence, specifically the PI-RADS 5 lesion and the PSA trajectory, overturned this by providing a strong indication for further investigation. The guideline criterion abstained because the panel was insufficient, leaving the retrieved documents as the deciding factor.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
